Horsmans Y, Desager J P, Hulhoven R, Harvengt C
Laboratoire de Pharmacothérapie, Université Catholique de Louvain, Brussels, Belgium.
J Clin Pharmacol. 1993 Oct;33(10):929-32. doi: 10.1002/j.1552-4604.1993.tb01924.x.
The pharmacokinetics of the H1-receptor antagonist cetirizine were studied from 0 to 72 hours after a single dose of 20 mg in 5 patients with chronic hepatocellular liver disease (group A), in 5 patients with chronic cholestatic liver disease (group B), and in 16 healthy volunteers. The renal function of patients and volunteers was normal (creatinine clearance > or = 70 mL/min). Cetirizine pharmacokinetics were similar in the two groups of patients. The elimination t1/2 was prolonged in patients (mean +/- standard deviation; group A: 14.32 +/- 2.30 hours; group B: 13.86 +/- 3.14 hours) in comparison with the values observed in volunteers (9.42 +/- 2.4 hours). A reduced apparent oral body clearance also was observed in patients (group A: .48 +/- .23 mL/min/kg; group B: .41 +/- .09 mL/min/kg) in comparison with volunteers (.74 +/- .19 mL/min/kg). No differences were observed in the mean cumulative urinary excretion between patients (group A: 69 +/- 15%; group B: 69 +/- 13%) and volunteers (70.7 +/- 7.8%).
对5例慢性肝细胞性肝病患者（A组）、5例慢性胆汁淤积性肝病患者（B组）及16名健康志愿者单次服用20毫克后0至72小时内H1受体拮抗剂西替利嗪的药代动力学进行了研究。患者和志愿者的肾功能均正常（肌酐清除率≥70毫升/分钟）。西替利嗪在两组患者中的药代动力学相似。与志愿者（9.42±2.4小时）相比，患者的消除半衰期延长（均值±标准差；A组：14.32±2.30小时；B组：13.86±3.14小时）。与志愿者（0.74±0.19毫升/分钟/千克）相比，患者（A组：0.48±0.23毫升/分钟/千克；B组：0.41±0.09毫升/分钟/千克）的表观口服清除率也降低。患者（A组：69±15%；B组：69±13%）与志愿者（70.7±7.8%）之间的平均累积尿排泄率未观察到差异。
